Clinical Trials Logo

Pulmonary Emphysema clinical trials

View clinical trials related to Pulmonary Emphysema.

Filter by:

NCT ID: NCT02100800 Completed - Emphysema Clinical Trials

Assessment of Emphysema Using 1.5T MRI With UTE Pulse Sequences

EMPHYREM
Start date: May 23, 2014
Phase: N/A
Study type: Interventional

Emphysema is a major pathological feature of Chronic Obstructive Pulmonary Disease (COPD). Non-invasive assessment of emphysema is a crucial issue for the phenotype and follow-up of COPD patients. Currently, CT is the method of reference to evaluate and quantify emphysema but it remains a radiation-based technique. Magnetic Resonance Imagery (MRI) with ultrashort echo time (UTE) pulse sequences is a promising non-ionizing alternative for lung imaging. Our objective is to evaluate emphysema in COPD patients using CT and MR-UTE, and to test the agreement between both techniques.

NCT ID: NCT02059057 Terminated - Emphysema Clinical Trials

LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)

CROSSOVER
Start date: December 2013
Phase: N/A
Study type: Interventional

Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).

NCT ID: NCT02056158 Completed - HIV Clinical Trials

HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium

Start date: January 13, 2014
Phase:
Study type: Observational

In HIV+ cigarette smokers, with no prior history of pulmonary infections, emphysema is often developed at an earlier age and is a significant cause of morbidity despite treatment with antiretroviral drugs. Preliminary data gathered from HIV+ individuals that smoke cigarettes strongly support the hypothesis that the combination of HIV infection and smoking creates increased stress in the lower respiratory tract. To examine the underlying factors that contribute to the accelerated development of emphysema in this cohort, samples from the lower respiratory tract will be provided by HIV+ and HIV- subjects. The samples collected will serve as biomarkers for assessing the onset of emphysema.

NCT ID: NCT02025205 Completed - Clinical trials for Endoscopic Lung Volume Reduction With Endobronchial Valve

Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study

IMPACT
Start date: August 2014
Phase: N/A
Study type: Interventional

The aim of this prospective, randomized, controlled, one-way crossover study is to assess and compare the efficacy of the Zephyr endobronchial valves vs. Standard of Care (SoC) in patients suffering from COPD with Homogeneous Emphysema. Patients will be followed up for 12 months after randomization. Patients in the SoC arm will crossover to the EBV treatment arm after the 6-month visit and will be followed up for 6 additional months.The primary objective is the variation of FEV1 between baseline and 3-month follow-up visit. The secondary objectives will evaluate quality of life, exercise capacity, dyspnea (including BODE index) changes, target lobe volume reduction, as well as safety outcomes.

NCT ID: NCT02022683 Completed - COPD Clinical Trials

To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves

TRANSFORM
Start date: January 28, 2014
Phase: N/A
Study type: Interventional

To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.

NCT ID: NCT02012673 Completed - COPD Clinical Trials

A Safety and Feasibility Study of Re-treating Patients With Severe Emphysema With the RePneu LVRC System.

RECOIL
Start date: January 2014
Phase: N/A
Study type: Interventional

Rationale: The combined data from 3 studies outside the Unites States investigating the Lung Volume Reduction Coil system (RePneu LVRC) showed statistically significant improvements in pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months post treatment. 24 months post treatment the improved pulmonary function and exercise capacity are slightly decreasing. Retreating the patient with the LVR coil system in other parts of the lung could potentially lead to new improvements in lung function, dyspnea, exercise capacity and quality of life and may reduce the rate of decline. Objective: To investigate the safety and feasibility of re-treating patients with severe Chronic Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system.

NCT ID: NCT02008162 Recruiting - COPD Clinical Trials

Bronchoreversibility and Radiologic Morphology of Emphysema

Start date: November 2009
Phase: N/A
Study type: Observational

To assess response to bronchodilation with tiotropium plus salbutamol in patients with severe emphysema and analyze relationships between bronchoreversibility response and semiquantitative computed-tomography based emphysema severity measures.

NCT ID: NCT02006576 Completed - Emphysema Clinical Trials

Prostaglandin Inhibition for Emphysema

PIE
Start date: January 1, 2014
Phase: Phase 2
Study type: Interventional

The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.

NCT ID: NCT01989182 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

The Spiration Valve System for the Treatment of Severe Emphysema

REACH
Start date: November 8, 2013
Phase: N/A
Study type: Interventional

This is a multicenter, prospective, randomized, controlled study being conducted in China to evaluate improvement of lung function after treatment with the Spiration Valve System as compared to medical management in the control group. The control group will be evaluated in the same manner as the treatment group. The Spiration Valve is a small, umbrella-shaped, one-way valve that is placed inside the airways of one lung. It is used to redirect air from the less healthy to the more healthy parts of the lung. This helps to reduce over-inflation and may improve overall lung function and quality of life for people living with emphysema.

NCT ID: NCT01983241 Active, not recruiting - Clinical trials for Pulmonary Emphysema in Alpha-1 PI Deficiency

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

SPARTA
Start date: November 2013
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.